0.051  0 (0%)		07-25 09:30
Open: 0.051 High: 0.051 Volume: 100		Pre. Close: 0.051 Low: 0.051 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.07	1-year :	0.08
Resists	First :	0.06	Second :	0.06
Pivot price	0.05
Supports	First :	0.05	Second :	0.04
MAs	MA(5) :	0.05	MA(20) :	0.05
	MA(100) :	0.05	MA(250) :	0.13
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	16.6	D(3) :	16.6
RSI	RSI(14): 38.4
52-week	High :	0.51	Low :	0.02

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BLPH ] has closed above bottom band by 44.8%. Bollinger Bands are 55.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.05 - 0.05	0.05 - 0.05
Low:	0.05 - 0.05	0.05 - 0.05
Close:	0.05 - 0.05	0.05 - 0.05

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Fri, 19 Jul 2024
Bellerophon Therapeutics (NASDAQ:BLPH) Research Coverage Started at StockNews.com - Defense World

Tue, 26 Dec 2023
Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology, Corp.’; Athersys, Inc.; Borqs Technologies, Inc.; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition Corp.; Evelo Biosciences, - StockTitan

Tue, 25 Jul 2023
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today? - InvestorPlace

Mon, 05 Jun 2023
Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today? - InvestorPlace

Sat, 27 May 2023
At 740%, this stock posted the single biggest gain of 2023. Can you guess it? - MarketWatch

Fri, 27 Jan 2023
7 Micro-Cap Stocks to Buy for Risk-Taking Investors - InvestorPlace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	12 (M)
Shares Float	10 (M)
Held by Insiders	15 (%)
Held by Institutions	8.7 (%)
Shares Short	90 (K)
Shares Short P.Month	124 (K)

EPS	-0.89
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.3
Profit Margin	-164.1 %
Operating Margin	-195.8 %
Return on Assets (ttm)	-78.5 %
Return on Equity (ttm)	-166 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0.46
EBITDA (p.s.)	-0.91
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.06
PEG Ratio	0
Price to Book value	0.16
Price to Sales	0.11
Price to Cash Flow	-0.06

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.